Nektar Therapeutics Q1 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : I have a few on BEMPEG. First, on melanoma and then a couple on lung. So you talked about the time to potential first data in that first-line melanoma study around year-end or early 2022. And I want to confirm whether that's based on the ORR interim? Or is that a PFS readout that you're referring to? And if it is ORR, then when do you expect the PFS results from that study to readout?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. And then on lung, what do you expect the average number of scans to be per patient in the PROPEL study by the time that it's presented? I know you talked about the patients all having a minimum of 2 scans, but I'm asking what the average number of scans you expect by then will be?

Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst : On 255, can you talk about the -- I know you've answered some of this before, but on the 2 scans, so that means if the interval is at least 2 weeks, then it's going to be essentially if somebody has responded early that they would be a confirmed response and then that duration would be at least 9 weeks? I'm wondering roughly how many patients do you think might be at that point? And then secondly, I was curious about your earlier stage stuff on other cytokines and platforms beyond polymer chemistry. What kind of things would you find interesting? And maybe additive or complementary to what you have now?